- Merck (NYSE:MRK): Q2 Non-GAAP EPS of $1.31 misses by $0.04; GAAP EPS of $0.48 misses by $0.34.
- Revenue of $11.4B (+21.9% Y/Y) beats by $200M.
- Neither the sales nor the EPS guidance ranges provided above include the impact of the potential launch of Merck’s COVID-19 antiviral drug candidate, molnupiravir.
- 2021 Guidance: Revenue of $46.4B-$47.4B (consensus: $46.55B); non-GAAP EPS: $5.47-$5.57 from prior guidance of $$6.48 - $6.68 (consensus: $5.61);
- Press Release
Merck EPS misses by $0.04, beats on revenue
Recommended For You
About MRK Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| MRK | - | - |
| Merck & Co., Inc. | ||